{"entity":{"id":"nct06198907","kind":"trial","name":"Golidocitinib in Combination With Sintilimab for PD-L1 Selected Treatment Locally Advanced or Metastatic Non-Small Cell Lung Cancer(NSCLC)","aka":["JACKPOT33"],"tldr":"A phase 2 trial of golidocitinib and sintilimab in lung cancer, run by Cancer Institute and Hospital, Chinese Academy of Medical Sciences, not yet recruiting.","summary":"Golidocitinib in Combination With Sintilimab for PD-L1 Selected Treatment Locally Advanced or Metastatic Non-Small Cell Lung Cancer(NSCLC) is a phase 2, interventional study registered as NCT06198907 by Cancer Institute and Hospital, Chinese Academy of Medical Sciences, with a registry enrolment figure of 69 participants, started 2024-01 and due to reach its primary completion in 2026-12. Interventions recorded: Golidocitinib; Sintilimab; platinum doublet chemotherapy. Conditions listed: Non-Small-Cell Lung Cancer. Primary outcome: Overall response rate (ORR) (cohort1); Progression-free survival (PFS) (cohort2). Lung eligibility wording from the registry: \"Histologically or cytologically confirmed non-small-cell lung cancer (NSCLC) , Stage IIIB/IIIC (not suitable for concomitant chemoradiotherapy) or Stage IV according to AJCC 8th\". Sites: China. No results are recorded here; the registry entry is the source.","status":"planned","asOf":"2026-09-25","links":[{"label":"ClinicalTrials.gov NCT06198907","url":"https://clinicaltrials.gov/study/NCT06198907"}],"tags":["ctgov-ingest","lung-deep-dive"],"related":[],"cancers":["nsclc"],"sections":[],"technologies":["checkpoint-inhibitor"],"targets":[],"drugs":["golidocitinib","sintilimab"],"companies":["dizal"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06198907","phase":"2","setting":"A Phase 2, Open-label, Single Arm Study to Investigate the Safety and Efficiency of Golidocitinib in Combination With Sintilimab in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With PD-L1TPS ≥ 1%)","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","enrolled":69,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06198907/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"drug":[{"id":"golidocitinib","kind":"drug","name":"Golidocitinib","route":"/drugs/golidocitinib/"},{"id":"sintilimab","kind":"drug","name":"Sintilimab","route":"/drugs/sintilimab/"}],"company":[{"id":"dizal","kind":"company","name":"Dizal Pharmaceutical","route":"/companies/dizal/"}],"term":[{"id":"lung-trials-open-today","kind":"term","name":"Lung cancer trials open today (registry snapshot)","route":"/terms/lung-trials-open-today/"}]}}